Stem Cell Therapy for Shoulder Pain: A Clinical Overview
Shoulder pain is one of the most common musculoskeletal complaints worldwide. For many people, it is not just discomfort — it is a months-long limitation that interferes with sleep, work, and basic daily movement. The rotator cuff, a group of tendons connecting the muscles around the shoulder joint, is responsible for the majority of cases. And rotator cuff injuries are notoriously difficult to treat well.
Standard options — physiotherapy, corticosteroid injections, and surgery — each carry limitations. Physiotherapy helps with mild cases but cannot repair structural damage. Steroid injections reduce inflammation temporarily but do not address the underlying tissue problem. Surgery can repair tears but comes with recovery time, re-tear risk, and variable outcomes. For patients stuck in the middle — too damaged to respond to conservative care, not quite ready or willing for surgery — stem cell therapy has emerged as a biologically grounded alternative worth understanding.
Why the Rotator Cuff Is So Hard to Heal
Tendons have poor natural healing capacity. Unlike muscle or bone, they have limited blood supply. When a tendon is torn or degenerates over time, the body’s repair process is slow and often incomplete. The tissue that forms in the healing process is frequently of lower quality than the original — less organised, less strong, and more prone to re-injury.
This is the core biological problem. It is not just that the tendon is damaged. It is that the environment around it does not support high-quality repair on its own. Inflammation persists, collagen organisation is disrupted, and the signalling that should coordinate healing becomes dysregulated.
How Stem Cells Work in the Shoulder
Mesenchymal stem cells work through two main mechanisms in the context of rotator cuff damage. First, they reduce local inflammation — calming the environment that is actively working against healing. Second, they release growth factors and signalling molecules that stimulate the surrounding tissue to organise and repair more effectively.
They do not simply replace damaged cells. They change the conditions in the tissue so that the body’s own repair capacity is enhanced. This is sometimes called a paracrine effect — the cells communicate with neighbouring tissue and shift its behaviour.
A study published in PubMed examined UC-MSCs specifically in a rotator cuff injury model. Treatment with UC-MSCs improved the structural organisation of tendon tissue, reduced inflammation, and supported recovery of collagen architecture compared to the control group. The findings confirmed that UC-MSCs have direct relevance to the kind of tendon damage seen in rotator cuff conditions.
What the Clinical Evidence Shows
The clinical evidence for MSC therapy in shoulder and rotator cuff conditions has grown steadily. A 2024 review published in PMC examined cell-based therapies for rotator cuff injuries across multiple human studies. It found that MSC therapy demonstrated a strong safety profile across all trials reviewed. Human studies suggested that MSC treatment may reduce re-tear rates after surgical repair and improve functional outcomes, though the authors noted that larger, more standardised trials are still needed.
A 2025 systematic review in PMC — focused specifically on MSC injections as an augmentation tool in rotator cuff repair — confirmed the safety of the approach and identified improvements in tendon-to-bone healing as the primary clinical benefit. The review concluded that MSC injections represent a promising addition to the treatment options available for this condition.
An earlier clinical study on direct MSC injection for partial rotator cuff tears reported meaningful pain reduction and improved shoulder strength at two years of follow-up, with no treatment-related adverse events throughout. Patients in the higher dose groups saw significant gains in both pain scores and functional strength measures.
Taken together, the evidence supports MSC therapy as a safe option with genuine biological rationale and early clinical signals of benefit. It is not yet at the level of a standard-of-care intervention — but it is well beyond experimental.
Who Is a Suitable Candidate
Not every patient with shoulder pain is appropriate for stem cell therapy. The best candidates tend to be those with partial-thickness rotator cuff tears or chronic tendinopathy who have not responded adequately to physiotherapy or injections. Patients considering stem cell therapy as an alternative to surgery — particularly those who want to avoid the risks and recovery time of an operation — are also a reasonable group to evaluate.
Full-thickness tears with significant structural damage may still require surgical repair, and in some cases MSC therapy is most useful as an adjunct to surgery rather than a standalone treatment. A physician assessment, typically with imaging, is necessary to determine where a patient falls on this spectrum.
Patients with active infection, certain inflammatory conditions, or other contraindications will not be suitable candidates. The decision to treat must be based on individual clinical assessment, not a general willingness to try regenerative medicine.
Why the Quality of the Clinic Matters
Shoulder anatomy is precise. The effectiveness of any injected therapy depends significantly on accurate, image-guided delivery to the right location within the joint and surrounding tissue. A clinic offering stem cell therapy for shoulder conditions should have the imaging capability and clinical expertise to deliver treatment precisely — not just the cells themselves.
Beyond delivery, cell quality matters. GMP-certified manufacturing, pre-treatment testing, and physician-led case review are the baseline requirements. Patients exploring this option should ask these questions directly before committing to any clinic.
About EDNA Wellness
EDNA Wellness is a surgeon-led regenerative medicine center in Bangkok, specializing in orthopedic and neurological conditions using Umbilical Cord–Derived Mesenchymal Stem Cells (UC-MSCs).
All cases are reviewed by orthopedic surgeons and neurosurgeons, with a focus on clinical indication, patient safety, and realistic treatment expectations. Stem cell therapy is recommended selectively, and alternative treatments are considered when more appropriate.
For more information or to book a consultation
LINE: @ednawellness
WhatsApp: +66 (0) 64 505 5599
References
- Kim, S.J. et al. (2020). Regeneration of a full-thickness defect in rotator cuff tendon with umbilical cord-derived mesenchymal stem cells in a rat model. PLOS ONE, PubMed. https://pubmed.ncbi.nlm.nih.gov/33166292/
- Haunschild, E.D. et al. (2024). Cell-based therapies for rotator cuff injuries: an updated review of the literature. International Journal of Molecular Sciences, PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC10970404/ Correia, J. et al. (2025). The role of injections of mesenchymal stem cells as an augmentation tool in rotator cuff repair: a systematic review. JSES Reviews, Reports, and Techniques, PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12047555/